HALF YEAR RESULTS 2026 For a future made possible by science. 1 © IP GROUP PLC 2026 | HALF YEAR RESULTS 2026 Disclaimer. Not for publication, distribution or release, directly or indirectly, in whole or in part, in or into the United States of…
HALF YEAR RESULTS 2026
For a future
made possible
by science.
1
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Disclaimer.
Not for publication, distribution or release, directly or indirectly, in
whole or in part, in or into the United States of America (including its
territories and dependencies, any state of the United States and the
district of Columbia), Canada, Australia, New Zealand, Japan, the
Republic of South Africa, the Republic of Ireland or to any resident
thereof or any other any jurisdiction in which such distribution or
release would be unlawful, or to any resident thereof. Any person into
whose possession any part of this presentation comes is required by
IP Group plc. (the “Company”) to inform himself/herself about and to
observe any applicable restrictions in his/her respective jurisdiction.
This presentation has not been approved by any applicable
competent authority (including the Financial Conduct Authority). This
presentation is for information purposes only and does not constitute
or form part of, and should not be construed as, an offer of, or a
solicitation to purchase or subscribe for, any securities , or an
inducement to enter into investment activity in the United Kingdom or
in any other jurisdiction in which such offer , sale, solicitation or
inducement is unlawful or to any person to whom it is unlawful to
make such offer , sale, solicitation or inducement. This presentation or
any part of it or the fact of its distribution shall not form the basis of, or
be relied on in connection with, any contract commitment or
investment decision in relation thereto nor does it constitute a
recommendation regarding the securities of the Company or any of
its subsidiary undertakings. No person must construe the information
contained in this presentation as legal, business, tax or investment
advice. Investors and prospective investors in the securities of the
Company or any of its subsidiary undertakings are required to make
their own independent investigation and appraisal of the business
and financial condition of the Company and the nature of the
securities, and consult his/her own independent counsel, business
advisor, tax advisor, investment advisor or any other authorised
advisors as to the legal, business, tax, investment or any other matters
pertaining to the Company and the securities of the Company.
This document is being made on the basis that the recipients keep
confidential any information contained herein or otherwise made
available, whether orally or in writing, in connection with the Company
2
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
and its subsidiary undertakings. This presentation may not be
recorded, copied, distributed, reproduced, stored in a retrieval system,
transmitted or passed on, directly or indirectly, in whole or in part, or
disclosed by any recipient, to any other person (whether within or
outside such person’s organisation or firm) or published in whole or in
part, for any purpose or under any circumstances, without the written
consent of the Company. Failure to comply with this restriction may
constitute a violation of applicable securities laws and/or a criminal
offence. By attending the presentation or by accepting this
presentation you will be taken to have represented, warranted and
undertaken that: (i) you have read and agree to comply with the
contents of this notice; (ii) you will treat and safeguard as strictly
private and confidential this presentation and its contents and any
comments made during the presentation and agree not to reproduce,
redistribute or pass on, directly or indirectly, to any other person or
publish, in whole or in part, for any purpose, such information. Your
obligations as set out in this disclaimer will continue in respect of the
information contained in this presentation until such time as, and then
only to the extent that, any such information is made available to the
public.
The Company or any subsidiary, member, employee, counsel, officer,
director, representative, advisor, agent or affiliate of the Company
does not have any obligation to update or otherwise revise any
statements reflecting circumstances arising after the date of this
presentation. To the extent permitted by applicable law, no
representation or warranty, express or implied, is made by the
Company or any subsidiary, member, employee, counsel, officer,
director, representative, advisor, agent or affiliate of the Company as
to the accuracy or completeness of any information contained in this
presentation. No information contained in this presentation is, or shall
be relied upon by any person as to its accuracy or completeness or as
a warranty, undertaking or representation by the Company.
The information contained in this presentation may constitute inside
information for the purposes of the Criminal Justice Act 1993 and the
UK version of the EU Market Abuse Regulation (2014/596/EU) which is
part of English law by virtue of the European Union (Withdrawal) Act
2018 ("MAR"). You should not use this information as a basis for your
behaviour in relation to any financial instruments (as defined in MAR),
as to do so could amount to a criminal offence of insider dealing
under the Criminal Justice Act 1993 or a civil offence of insider dealing
for the purposes of MAR or other applicable laws and/or regulations in
other jurisdictions.
Nothing contained in this presentation shall be deemed to be a profit
forecast or profit estimate. This presentation may contain certain
forward-looking statements, estimates, beliefs or opinions with
respect of the financial condition and business operations of the
Company as well as certain plans and objectives of the Company. By
their nature, statements involve risk and uncertainty, because they
depend on circumstances and events that may or may not occur in
the future and may be based on various assumptions, which are
inherently subject to significant uncertainties and contingencies
which are difficult or impossible to predict and are beyond the
Company's control. Past performance of the Company cannot be
relied on as a guide to future performance, and any actual results and
developments may differ materially from those expressed in or
implied by such statements. The Company can give no assurance
that such expectations will prove to have been correct and the
Company therefore cautions any person not to place undue reliance
on statements which speak only as at the date of this presentation.
The statements contained in this presentation are made as at the
date of this presentation. The distribution of this presentation shall
under no circumstances imply that there shall not be a change in the
Company’s affairs since the date of this presentation or that the
information contained in this presentation is correct as of any date
subsequent to the date of this presentation.
The Company and its subsidiary undertakings expressly disclaim any
and all liability that may be based on any information contained in
this presentation and any errors or omissions herein. No person is
authorised to give any information not contained in this presentation
and any information not contained in this presentation must not be
relied upon as having been authorised by or on behalf of the
Company.
Contents.
01
Half year overview
02
Portfolio progress &
future value opportunity
03
Financial results
04 Summary & Q&A
3
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
01
Half year overview
4
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
£1.7bn.
Industry
pioneers
backing
science and
technology.
5
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Cumulative
investment
600+.
15,000+.
Companies
formed and
supported
Jobs created by
companies
backed
Half year overview.
Continued
NAV growth.
114p vs 110p (FY25)
~117p as at 11 Sep 2026
6
Significant
de-risking of Pfizer’s
lead obesity
programmes.
Strong balance sheet
& realisations.
Portfolio delivering key
operational milestones.
Further positive data released by
Pfizer for berobenatide.
Cash proceeds of £69m;
surpassing total for FY25.
Portfolio companies raised
£543m in H1.
£27m uplift to £152m.
Strong balance sheet; gross
cash & deposits £239m.
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Significant de-risking of Pfizer’s
lead obesity programmes.
Financial exposure to Pfizer’s obesity drug franchise, including
lead Phase 3 berobenatide, Phase 2b berobenatide/amylin
combination and others.
Berobenatide.
- Further positive clinical data
released by Pfizer
- Supports a monthly maintenance regimen
Pfizer progressing 10 Phase 3
studies this year, with launch
targeted in 2028.
Berobenatide/
amylin combination.
Advanced into P2b in May’26,
triggering £27m uplift
Obesity market of
c.$95–145bn.
p.a. by 2030
Berobenatide – previously known as PF’3944 or MET-097i
Market size is a range of sell-side estimates for 2030 on a net revenue basis (Goldman Sachs Research c.$95bn; Morgan Stanley Research c.$105bn base case, up to c.$144bn), is not directly comparable to list-price
market data and excludes GLP-1 sales for type 2 diabetes. Pfizer programme names: MET-097i = PF’3944 (berobenatide), MET-233i = PF’3945 (amylin), MET-034i = PF’4696 (GIPR agonist), MET-815i = PF’6795 (berobenatide
prodrug).
7
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
£27m
Obesity market of
Pfizer obesity programmes –
route to market.
2026
Berobenatide weekly
VESPER-4 and 5 (± T2D)
Berobenatide monthly
VESPER-6
Berobenatide label expansion
OSA, knee OA, switch, China, Japan
Amylin combination
berobenatide + PF’3945
Amylin monotherapy
PF’3945 alone
Other programmes
oral and two Ph1 assets
Ph1/2a
Ph1
c.$95–145bn.
p.a. by 2030
2027
2028
2029
2 Phase 3 studies
Regulatory review
Primary completion Oct 2027
Approval estimated 2028
1 Phase 3 study
Regulatory review
Primary completion May 2028
Approval estimated mid-2029
7 further Phase 3 studies estimated to read out during 2028
Review
Primary completion from 2028
Approvals est. 2029
Phase 2b, SOLIS-1
Phase 3
Regulatory review
Primary completion Apr 2027
Not yet started
Approval est. end 2029
Phase 2b, SOLIS-1
Phase 3
Regulatory review
Same study, completion Apr 2027
If pursued
If pursued
Phase 1
Berobenatide prodrug, GIPR agonist & berobenatide
Phase 2
Phase 3
Trial primary completion dates are sponsor estimates per ClinicalTrials.gov as at August 2026 and are subject to revision. Dashed boxes denote programmes or regulatory reviews not yet initiated; where such a box is
divided, the diagonal indicates that the split between phases is indicative only. Approval dates, phase progression and launch dates reflect management estimates only; regulatory approval is not assured and there can
be no guarantee that any royalties will be received. Market size is a range of sell-side estimates for 2030 on a net revenue basis (Goldman Sachs Research c.$95bn; Morgan Stanley Research c.$105bn base case, up to
c.$144bn), is not directly comparable to list-price market data and excludes GLP-1 sales for type 2 diabetes. Pfizer programme names: MET-097i = PF’3944 (berobenatide), MET-233i = PF’3945 (amylin), MET-034i = PF’4696
(GIPR agonist), MET-815i = PF’6795 (berobenatide prodrug).
8
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
2030
Review
Oxford Nanopore: A clearer view of biology.
“In the long-term, Oxford Nanopore’s sensing technology can integrate
information about the molecules of life with AI-driven information systems
of the future, towards a healthier world, enabled by biological
intelligence.”
Strengthened leadership team for scaleup. CEO Francis Van Parys joined March
2026, with further leadership appointments across key capabilities.
Strong H1 financial progress; gross margin up 400bps to 62.2% and adj. EBITDA
loss more than halving to £22.1m
A focused strategy to deliver 2030 targets and build towards a $1bn+ revenue
business.
A differentiated platform with a clear
path to broader adoption and durable
performance.
Clear near-term path to profitability and cash generation. FY26 guidance
unchanged; on track for adj. EBITDA breakeven in FY27 and positive FCF in FY28.
New cross-licensing arrangement with a global diagnostics company; $35m of
committed revenue across FY26–FY28 and ongoing royalties.
9
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Portfolio attracts £0.5bn & delivers key milestones.
10
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Continued strong realisations; strong balance sheet.
HY26 exits.
£69m.
Surpasses total
delivered in FY25
Strong balance
sheet.
£239m.
Cash and deposits
11
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
+£23m
+£18m
+£17m
We back companies from start-up to scale-up.
INVESTEE COMPANY STAGE
Series B+
Pre-Seed / Seed & Series A
PROPORTION OF CAPITAL
IP Group’s EIS business
1
2
Private funds
managed by IP Group
Dedicated EIS funds with
world class universities
Permanent balance sheet capital
Science & tech scale up capital
AUM1:
~£360m
NAV1:
~£1bn
AUM1,2:
~£200m+
As of 30th June 2026
Includes 3rd party fund commitments only. All FX conversions as of 30 June 2026 (AUD/GBP: 0.5190).
12
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Expanding third party capital platform and AUM.
£0.5bn
3rd party capital
managed
13
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Strategic relationship
with Aberdeen
progressing with first new
investments expected
shortly.
IP Group launches
Climate Catalyst Fund
with the CEFC to help
scale Aus technologies
aimed at hard to abate
industries.
02
Portfolio progress
& future value
opportunity
14
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Total Portfolio.
17p
ROYALTIES*
11p
£152m
10p
£461m
£100m
£907m.
9p
3p
£89m
£79m
£26m
*The group benefits from financial exposure to Pfizer’s obesity drug franchise including Phase 3 PF’3944 alongside several other programmes
Figures shown in pence reflect pence per share values.
15
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
53p
Rest of portfolio
103p
Total portfolio
Successful exit: Centessa.
IP Group first invested in ApcinteX,
University of Cambridge spin-out, in
2017.
£36m.
ApcinteX acquired by Centessa
in Feb 2021.
£7.3m.
Total Proceeds1
HY26 FV Change
Centessa IPO on Nasdaq in June
2021.
Centessa acquired by Eli Lilly in 2026
for upfront cash consideration of
$6.3bn + up to further $1.5bn in
milestone payments.
~24%.
Realised IRR
From breakthrough science to
successful exit – demonstrating the
value creation potential of our life
sciences portfolio.
1 Total proceeds comprises £18.1m received during FY26, £7.2m in FY25, £10.6m in FY24. Additional CVR payments of up to $5.6m/£4.2m may be received subject to achievement of milestones
16
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Life sciences: clinical momentum in therapeutics.
17
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
2 of our quantum companies raised $0.5bn.
18
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Next-generation compute for AI processing.
Memory
Light
IPG Value
IPG%
£8.9m.
26.3%.
Iris system now runs
billion-parameter LLMs.
19
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
IPG Value
£10.8m.
Probability
IPG%
IPG Value
IPG%
27.8%.
£1.8m.
17.0%.
Next-generation
ReRAM memory.
Closed new funding round.
Probabilistic-computing
company.
03
Financial results
Strong balance sheet &
realisations
20
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Summary financials.
Net Asset Value (NAV).
Increase in NAV/sh.
Net overheads.
Gross cash.
113.9pps
+3.2%
£7.9m
£238.9m
(FY25 110.4pps)
(FY25 +13%)
(HY25 £7.4m)
(FY25 £211.0m)
£1,006.4m (FY25 £975.1m)
21
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Results: Balance sheet - net assets.
Portfolio movements:
Portfolio
Net Cash
Other net liabilities
£30m
NAV
£975m
NAV
£1,006m
£908m
£907m
(£69m)
£38m
£908m
£907m
£88m
(£21m)
£119m
(£20m)
FY 2025
HY 2026
2
22
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
1
Opening
Investment
Exits
Fair Value
Gain
Closing
Pfizer royalty asset – risk-adjusted NPV.
Probability of
success
Probability of
success
Probability of
success
Total: £152m
53%
39%
10%
£12m
Launch date
Launch date
Launch date
Peak sales
Peak sales
Peak sales
2028
$3.5bn
£76m
berobenatide
2030
$4.8bn
2030
$3.7bn
£76m
£62m
berobenatide & amylin
£62m
Not yet valued
£12m
0
oral
berobenatide & GIPR
agonist
£1m
amylin monotherapy berobenatide prodrug
NOTE: all launch dates, probabilities of success and peak sales reflect management estimates.
Approval timing reflects management estimates only. Regulatory approval is not assured and there can be no guarantee that any royalties will be received.
Pfizer programme names: MET-097i = PF’3944 (berobenatide), MET-233i = PF’3945 (amylin), MET-034i = PF’4696 (GIPR agonist), MET-815i = PF’6795 (berobenatide prodrug).
23
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
£1m
All programmes
Portfolio funding profile.
Portfolio
funding
profile.
Companies
£4m value
representing
87% of equity
and debt
investments
Our portfolio.
For the larger companies in the portfolio:
10%
21%
21%
funded to expected profitability
6%
6%
44%
19%
need to raise in 2026
19%
24
Funded to breakeven
Next 6 months
12 to 24 months
24 months +
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
6 to 12 months
need to raise in first half of 2027
Group cash flow summary.
(£7.9m)
£211.0m
(£3.1m)
£0.1m
£238.9m
£68.7m
(£29.9m)
Opening gross
25
Investment
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Realisations
Opening
Closing
Gross
211.0
238.9
Debt
(122.8)
(119.8)
Net
88.2
119.1
Overheads
Repayment of debt
Other
Closing gross
04
Summary
For a future made
possible by science
26
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Half year overview.
Continued
NAV growth.
114p vs 110p (FY25)
~117p as at 11 Sep 2026
27
Significant
de-risking of Pfizer’s
lead obesity
programmes.
Strong balance sheet
& realisations.
Portfolio delivering key
operational milestones.
Further positive data released by
Pfizer for berobenatide.
Cash proceeds of £69m;
surpassing total for FY25.
Portfolio companies raised
£543m in H1.
£27m uplift to £152m.
Strong balance sheet; gross
cash & deposits £239m.
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
FY26 priorities and future areas of focus.
Continue positive NAV per share performance
First investments from new scale-up capital vehicle
Announce at least one further private capital vehicle
Deliver cash exits exceeding £250m by end of 2027
Maintain shareholder-focused capital allocation policy
28
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Q&A
29
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
05
Appendices
30
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
1 | Board.
Michael Queen
Greg Smith
David Baynes
Previously CEO of 3i Group plc, Chair of
Coller Capital; extensive experience in
public & private sectors as former member
of Prime Minister’s Business Advisory
Group; former Chair of BVCA.
Decade as Group CFO driving strategy,
scale and geographic expansion. Deep
experience in investment appraisal, capital
and resource allocation.
Previously KPMG and $3bn fund of hedge
funds.
Finance and venture background, long
track record of working successfully with
the Boards of investee companies
Co-founder Fusion IP plc; bought by IP
Group.
Aedhmar Hynes
Heejae Chae
Dr Caroline Brown
Background in communications advising
brands through digital transformation and
technology disruption. Ranked among the
‘PR Week’ 50 most powerful
communications professionals in the
world.
Experienced public company director.
Former CEO of AIM-listed Scapa Group plc,
a global supplier of products for
healthcare and industrial markets.
Background in corporate finance, advising
global corporations and governments.
Experience in managing early stage
companies in energy and tech sectors.
Anita Kidgell
Angela Leach
Non-executive Chairman
Non-executive Director
Non-executive Director
25 years of pharmaceutical experience.
Head of Corporate Strategy at GSK leading
strategic initiatives in China, ESG,
geopolitics, integrations and demergers.
31
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Chief Executive Officer
Non-executive Director
Company Secretary and
Group Legal Counsel
Background in corporate, commercial and
IP law.
Previously CMS Cameron McKenna and
Memery Crystal.
Chief Financial and Operating Officer
Non-executive Director
2 | Executive team.
Greg Smith
David Baynes
See bio on previous page.
See bio on previous page.
Company Secretary and
Group Legal Counsel
Dr Mark Reilly
Anthony York
Chris Glasson
Background in software, web, optics, and
electronics. Previously Remarkable
Innovation, a technical due diligence
company with Fortune 500 and national
government clients.
Proven capability of developing and leading
high-performing teams. Specialising in
development of both HR and Reward
strategies that directly support commercial
growth objectives.
Chartered accountant with 20 years+
experience in finance.
Previously: Deloitte, Tesco, The Carphone
Warehouse.
Liz Vaughan-Adams
Moray Wright
Joyce Xie
Background in crisis management, M&A,
IPOs, fund raisings, media relations, CSR and
digital strategies.
20 years experience with corporate and
financial institutions and sits on the board of
several Parkwalk companies.
Previously: Hoare Govett, JP Morgan, Lazard
and Mirabaud.
International career in investment
management and investment banking.
Previously: HSBC investment banking,
portfolio management.
Chief Executive Officer
Managing Partner
Director of Communications
Mike Molinari
Managing Director, Australia
Background in company development and
scientific research, with a passion for
fundamental scientific discovery.
Previously: McKinsey & Company
32
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Chief Financial and Operating Officer
Group People Director
CEO Parkwalk Advisors
Angela Leach
See bio on previous page.
Group Finance Director
Managing Director, Global Capital
3 | Differentiated UK sourcing.
Our specialist EIS business
~£360m AUM
Partnered with leading
UK universities
2026 updates
£200m+
returned to
investors
since
inception.
Largest EIS
Fund in the
market, by
fundraise.
25 deals
completed
in H1 2026.
Most active
investor in
UK uni
spin-outs.
£50m avg. invested per
tax year over last 10
years
100+ current portfolio
companies
15+ year track record
33
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
4 | Therapeutics: clinical stage portfolio.
Positive results received
Timing reflects current best estimate of study completion, which is subject to change; data typically reported several months later
THERAPEUTICS
PORTFOLIO
ONCOLOGY
INFLAMMATION
IP GROUP
VALUE
COMPANY
ESTIMATED STUDY COMPLETION
2026
2027
£16.0m
Phase 1
Phase 2
£18.4m
Phase 1b
£13.3m
Phase 2a Alno
Phase 2 Alno
< £10m
Phase 1 IKS014
Phase 1 IKS03
< £5m
Phase 1b
Phase 2
£26.2m
Phase 1b
£19.5m
Phase 1
< £10m
OTHER
Phase 1 APL-10456
1
Phase 1/2a PF’3945
< £10m
Phase 2a
< £5m
Phase 3
Phase 2b Camo
Ph3 PF’3944
£361.6m
1.
34
2028
£88.6m
£152.1m
Metsera/Pfizer milestones reflect the two most advanced programmes, Berobenatide (PF’3944) and the Amylin combination (PF’3945 & PF’3944).
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Negative results received
Ph2b PF’3945
Phase 2 Polθ
Phase 2 APL-10456
5 | Portfolio by valuation method (FY25 vs HY26).
Quoted
15%
Recent Financing < 12 months
19%
Recent Financing > 12 months
17%
Future event
Adjusted funding based
on past performance
6%
DCF / Revenue multiple
25%
Debt
LP Statement
8%
5%
5%
FY25
35
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
11%
19%
21%
7%
6%
27%
5%
4%
HY26
We are investing
today in science,
addressing the
world’s greatest
unmet challenges
6 | Impact is in our DNA.
IMPACT AT OUR CORE
GROUP LEVEL
PORTFOLIO LEVEL
By the numbers.
Impact is a
strategic driver
for IP Group.
Tech-enriched
future.
Regenerative
future.
Healthier
future.
Impact is one of our five
strategic pillars and is a
fundamental component of
our business model and
corporate strategy
We back deeptech
companies and future
computing solutions, that
enable the digital
economy, and generate
prosperity for all
We invest in science,
addressing the global
climate challenge, and
back innovators and
pioneers, creating
revolutionary climate
technology solutions
We invest in breakthrough
therapeutics, which focus
on cure and prevention
rather than only treating
symptoms
£1.5bn1
AUM in science-based
businesses
600+
companies backed across
cleantech, healthtech and
deeptech
15k+
jobs created by the companies
we have backed
Note: The use by IP Group plc of any MSCI ESG research llc or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation,
or promotion of IP Group plc by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.
1.
£1,006m NAV + £553m 3rd party AUM as of 30 June 2026.
36
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
7 | Shareholder register (above 2% holders).
Shareholder register
% holding
Railways Pension Scheme
18.4%
BlackRock
6.2%
Vanguard
5.3%
Legal & General Investment Management
3.9%
Imperial College
3.5%
Societe Generale collateral account
3.2%
Janus Henderson
3.2%
Lansdowne Partners
2.4%
Aberdeen
2.3%
Schroder Investment Management
2.1%
Additional TR-1 disclosures*
% including exposure through financial instruments
Saba Capital
12.1%
Jefferies Financial Group
5.0%
*Source: RD:IR database as at 04 Sept 2026; *TR1 filings which may duplicate underlying shares
37
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
© IP GROUP PLC 2026 | HALF YEAR RESULTS 2026
Visionary ventures
for a future made
possible by science.
2nd Floor, 3 Pancras Square,
King’s Cross,
London, N1C 4AG
Tel: +44 (0) 20 7444 0050
Web: www.ipgroupplc.com